Alembic Pharma
Ticker > Company >

Alembic Pharma share price

Alembic Pharmaceuticals Ltd.

NSE: APLLTD BSE: 533573 SECTOR: Pharmaceuticals & Drugs  2.08 L   938   156

808.80
-4.65 (-0.57%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 813.3

Today's Low

₹ 792.7

52 Week High

₹ 1029.5

52 Week Low

₹ 635.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 15898.03 Cr.

Enterprise Value

₹ 17018.78 Cr.

No. of Shares

19.66 Cr.

P/E

24.82

P/B

2.83

Face Value

₹ 2

Div. Yield

1.5 %

Book Value (TTM)

₹  285.67

CASH

₹ 28.74 Cr.

DEBT

₹ 1149.49 Cr.

Promoter Holding

69.87 %

EPS (TTM)

₹  32.58

Sales Growth

10.26%

ROE

11.85 %

ROCE

11.31%

Profit Growth

27.29 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alembic Pharmaceuticals Ltd.

Azithral TELLZY ZEET Elena Corazon MEGACARE ZENOM CORIUM GASTRON ENTERON Maxis Ouron

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.26%
3 Year8.91%
5 Year5.59%

Profit Growth

1 Year27.29%
3 Year22.69%
5 Year-10.2%

ROE%

1 Year11.85%
3 Year12.04%
5 Year10.74%

ROCE %

1 Year11.31%
3 Year12.56%
5 Year11.32%

Debt/Equity

0.2047

Price to Cash Flow

19.64

Interest Cover Ratio

8.5611

CFO/PAT (5 Yr. Avg.)

1.14221012480095

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 69.87 0.00
Mar 2026 69.74 0.00
Dec 2025 69.74 0.00
Sep 2025 69.74 0.00
Jun 2025 69.67 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 22.6943287260549% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 8.5611.
  • Company’s PEG ratio is 0.909653765118475.
  • The company has an efficient Cash Conversion Cycle of 65.4738 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.14221012480095.
  • The company has a high promoter holding of 69.87%.

 Limitations

  • The company has shown a poor revenue growth of 8.90870286620473% for the Past 3 years.
  • Tax rate is low at 2.0929.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 1570.64 1494.17 1796.24 1642.24 1718.74
Total Expenditure 1399.98 1280.43 1492.93 1370.63 1444.67
Operating Profit 170.66 213.74 303.31 271.61 274.07
Other Income 13.21 7.79 11.49 10.73 25.88
Interest 23.71 22.64 22.81 21.65 19.42
Depreciation 68.6 73.37 75.64 79.67 82.31
Exceptional Items 0 0 0 -42.24 -24.76
Profit Before Tax 91.56 125.52 216.35 138.78 173.46
Tax 16.22 22 36.99 24.31 -69.61
Profit After Tax 75.34 103.52 179.36 114.47 243.07
Adjusted EPS (Rs) 3.83 5.27 9.13 5.82 12.37

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 5035.4 5149 5874.06 6032.63 6651.38
Total Expenditure 4126.63 4484.97 4876.27 5136.55 5589.14
Operating Profit 908.77 664.03 997.79 896.08 1062.24
Other Income 51.17 3.85 32.05 53.19 56.37
Interest 17.02 49 54.47 76.47 86.51
Depreciation 284.92 272.95 271.14 277.08 311
Exceptional Items 0 0 0 12.87 -66.99
Profit Before Tax 658 345.93 704.23 608.59 654.11
Tax 114.45 -0.8 37.75 105.47 13.69
Net Profit 543.55 346.73 666.48 503.12 640.42
Adjusted EPS (Rs.) 27.65 17.64 33.91 25.6 32.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 39.31 39.31 39.31 39.31 39.31
Total Reserves 5251.03 4374.98 4869.6 5155.43 5575.95
Borrowings 0 0 0 0 0
Other N/C liabilities 204.25 86.67 83.59 84.51 0.17
Current liabilities 1694.45 1551.3 1368.4 2285.86 2425.02
Total Liabilities 7189.04 6052.26 6360.9 7565.11 8040.45
Assets
Net Block 1771.1 2377.47 2535.66 2513.47 2828.42
Capital WIP 2205.8 601.28 524.36 837.23 633.7
Intangible WIP 98.44 0 0 0 49.7
Investments 219.36 229.27 226.68 259.56 271.4
Loans & Advances 34.88 64.03 44.46 102.39 157.36
Other N/C Assets 0 0 0 0 30
Current Assets 2859.46 2780.21 3029.74 3852.46 4069.87
Total Assets 7189.04 6052.26 6360.9 7565.11 8040.45
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 658.01 345.93 704.23 608.59 654.11
Adjustment 413.35 448.49 284.21 365.07 428.45
Changes in Assets & Liabilities -397.3 -10.39 -205.64 -701.44 -193.57
Tax Paid -128.8 -53.78 -10.03 -45.65 -79.53
Operating Cash Flow 545.26 730.25 772.77 226.57 809.46
Investing Cash Flow -368.72 -460.98 -329.02 -636.08 -483.43
Financing Cash Flow -216.64 -261.16 -445.29 403.61 -317.59
Net Cash Flow -40.1 8.11 -1.54 -5.9 8.44

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 69.67 69.74 69.74 69.74 69.87
alembic limited 28.54 28.54 28.54 28.54 28.54
barkha pranav amin 0.03 0.03 0.03 0.03 0.03
chirayu ramanbhai amin 2.13 2.13 2.13 2.13 2.13
chirayu ramanbhai amin hu... 0.05 0.11 0.11 0.11 0.11
gallup trust (pranav chir... 0.05 0.05 0.05 0.05 0.05
inaaya shaunak amin 0.04 0.04 0.04 0.04 0.04
krupa shaunak amin 0.03 0.03 0.03 0.03 0.03
malika chirayu amin 1.53 1.53 1.53 1.53 1.53
naintara shaunak amin 0.04 0.04 0.04 0.04 0.04
nirayu private limited - 35.65 35.65 35.65 35.78
pranav chirayu amin 0.51 0.51 0.51 0.51 0.51
ranvir pranav amin 0.02 0.02 0.02 0.02 0.02
samira pranav amin 0.02 0.02 0.02 0.02 0.02
satori trust (chirayu ram... 0.03 0.03 0.03 0.03 0.03
shaunak chirayu amin 0.51 0.51 0.51 0.51 0.51
udit chirayu amin 0.51 0.51 0.51 0.51 0.51
nirayu limited 35.64 - - - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 30.33 30.26 30.26 30.26 30.13
dsp small cap fund - - - - 3.86
icici prudential pharma h... - - 1.06 1.12 1.38
investor education and pr... - 0.83 0.82 - 0.80
kotak small cap fund 1.74 1.74 1.74 1.74 1.74
life insurance corporatio... 4.32 4.32 4.32 4.32 4.32
llp - 0.01 0.01 0.01 0.28
tata aia life insurance c... 1.15 1.57 1.86 1.81 1.15
dsp midcap fund 4.66 4.55 4.23 4.23 -
investor education and pr... 0.78 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Monarch Networth Capital
Research BOB Capital Market
Research Monarch Networth Capital
Research BOB Capital Market
Research ICICI Securities Limited
Research HDFC Securities
Research HDFC Securities
Research HDFC Securities
Research ICICI Securities Limited
Research HDFC Securities
Research Monarch Networth Capital
Research BOB Capital Market
Research BOB Capital Market

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q4FY22
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
Concall Q1FY21
Concall Q3FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY20
Presentation Q3FY26
Presentation Q3FY26
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY21
Presentation Q3FY20

Company News

 No Latest News available for this company.Report us

Alembic Pharma Stock Price Analysis and Quick Research Report. Is Alembic Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Alembic Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Alembic Pharma has a PE ratio of 24.9287159041033 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Alembic Pharma has ROA of 8.2076% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Alembic Pharma has a Current ratio of 1.6783.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Alembic Pharma has a ROE of 11.8487%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Alembic Pharma has a Debt to Equity ratio of 0.2047 which means that the company has low proportion of debt in its capital.

  • Sales growth: Alembic Pharma has reported revenue growth of 10.2567% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Alembic Pharma for the current financial year is 15.9702197138037%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Alembic Pharma is Rs 12 and the yield is 1.4715%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Alembic Pharma is Rs 32.5809. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Alembic Pharma in Ticker for free. Also, one can get the intrinsic value of Alembic Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Alembic Pharma FAQs

Q1. What is Alembic Pharma share price today?
Ans: The current share price of Alembic Pharma is Rs 812.2.

Q2. What is the market capitalisation of Alembic Pharma?
Ans: Alembic Pharma has a market capitalisation of Rs 15964.85693128 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Alembic Pharma?
Ans: The PE ratio of Alembic Pharma is 24.9287159041033 and the P/B ratio of Alembic Pharma is 2.84311879139797, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Alembic Pharma share?
Ans: The 52-week high share price of Alembic Pharma is Rs 1029, and the 52-week low share price of Alembic Pharma is Rs 635.8.

Q5. Does Alembic Pharma pay dividends?
Ans: Currently, Alembic Pharma pays dividends. Dividend yield of Alembic Pharma is around 1.4715%.

Q6. What are the face value and book value of Alembic Pharma shares?
Ans: The face value of Alembic Pharma shares is Rs 2, while the book value per share of Alembic Pharma is around Rs 285.6722. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Alembic Pharma?
Ans: Alembic Pharma has a total debt of Rs 1149.49 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Alembic Pharma?
Ans: The ROE of Alembic Pharma is 11.8487% and ROCE of Alembic Pharma is 11.3057%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Alembic Pharma a good buy for the long term?
Ans: The Alembic Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Alembic Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Alembic Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Alembic Pharma’s financials?
Ans: You can review Alembic Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Alembic Pharma

Alembic Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page for Alembic Pharmaceuticals Ltd., a prominent pharmaceutical company in India. In this comprehensive analysis, we will delve into various aspects of the company, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders.

Alembic Pharmaceuticals Ltd Share Price

Stay updated on the latest share price of Alembic Pharmaceuticals Ltd. and monitor its performance in the stock market. Ticker provides real-time share price data, allowing you to track the stock's movement and make well-informed investment decisions.

Alembic Pharmaceuticals Ltd Balance Sheet

Gain insights into the balance sheet of Alembic Pharmaceuticals Ltd., an essential financial statement that provides details about the company's assets, liabilities, and shareholders' equity. Utilize ticker premium feature, the DCF Analysis, to calculate the fair value of the company based on its balance sheet.

Alembic Pharmaceuticals Ltd Annual Report

Access the annual reports of Alembic Pharmaceuticals Ltd., which offer a comprehensive overview of the company's performance, achievements, and strategic initiatives. These reports are conveniently available for download on Ticker, enabling you to analyze the company's financials in detail.

Alembic Pharmaceuticals Ltd Dividend

Stay informed about the dividend payouts of Alembic Pharmaceuticals Ltd. to its shareholders. Explore the history of dividends, dividend yield, and dividend payment dates. Ticker pre-built screening tools can assist in identifying stocks with consistent and attractive dividend payouts.

Alembic Pharmaceuticals Ltd Quarterly Results

Analyze Alembic Pharmaceuticals Ltd.'s quarterly results, including revenue, profit, and key financial metrics. Utilize ticker premium features, such as BVPS Analysis, Earnings multiple approach, and DuPont analysis, to gain a deeper understanding of the company's financial performance.

Alembic Pharmaceuticals Ltd Stock Price

Track the historical stock price of Alembic Pharmaceuticals Ltd. using our interactive price charts. Ticker provides customizable charts with various timeframes, technical indicators, and overlays, enabling you to evaluate the stock's performance effectively.

Alembic Pharmaceuticals Ltd Price Chart

Analyze the stock price movements of Alembic Pharmaceuticals Ltd. through ticker user-friendly price chart. Customize the chart to view key trends, patterns, and support/resistance levels that can assist you in making well-informed investment decisions.

Alembic Pharmaceuticals Ltd News

Stay up to date with the latest news and developments related to Alembic Pharmaceuticals Ltd. Ticker platform curates news articles to keep you informed about the company's performance, industry trends, and market dynamics.

Alembic Pharmaceuticals Ltd Concall Transcripts

Explore the concall transcripts of Alembic Pharmaceuticals Ltd., which provide detailed records of the company's conference calls with analysts and investors. Through these transcripts, you can gain valuable insights into the company's future plans, strategies, and overall outlook.

Alembic Pharmaceuticals Ltd Investor Presentations

Access the investor presentations of Alembic Pharmaceuticals Ltd., which offer a comprehensive overview of the company's business model, growth prospects, and investment opportunities. These presentations provide valuable insights into the company's operations and strategic initiatives.

Alembic Pharmaceuticals Ltd Promoters

Learn about the key promoters of Alembic Pharmaceuticals Ltd., the individuals or entities who have played a significant role in establishing and expanding the company. Gain insights into their background, contributions, and shareholding patterns.

Alembic Pharmaceuticals Ltd Shareholders

Understand the shareholder base of Alembic Pharmaceuticals Ltd. and the distribution of ownership among various categories of investors. Analyze the institutional and retail investor participation to gauge market sentiment towards the stock.

Experience the power of comprehensive stock analysis with Alembic Pharmaceuticals Ltd. Ticker provides a range of pre-built screening tools, downloadable annual reports, and real-time stock data to assist you in making informed investment decisions. Start exploring today!

Alembic Pharmaceuticals Ltd ROCE

Return on Capital Employed (ROCE) is a critical financial measure reflecting Alembic Pharmaceuticals Ltd's profitability and efficiency in utilizing its capital investments effectively. Visitors can find the ROCE data for Alembic Pharmaceuticals Ltd in the financials table or ratio section above, gaining valuable insights into how effectively the company generates profits from the capital employed in its operations.

Alembic Pharmaceuticals Ltd EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) serves as a key indicator of Alembic Pharmaceuticals Ltd's operational performance and cash flow generation. By excluding interest, taxes, and non-cash expenses like depreciation and amortization, EBITDA provides insights into the company's core profitability. Investors can analyze the EBITDA data for Alembic Pharmaceuticals Ltd in the financials table or ratio section above for a comprehensive evaluation of the company's financial health.

Alembic Pharmaceuticals Ltd DPS

Dividends Per Share (DPS) is a significant metric for income-seeking investors, reflecting the dividends paid out by Alembic Pharmaceuticals Ltd in relation to its share count. The DPS data for Alembic Pharmaceuticals Ltd can be accessed in the financials table or ratio section above, enabling investors to assess the company's dividend payment history and dividend yield.

Alembic Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) is a widely-used financial metric evaluating Alembic Pharmaceuticals Ltd's profitability on a per-share basis. By dividing the net income by the number of outstanding shares, EPS offers insights into the company's earnings potential and growth trajectory. Visitors can refer to the EPS data for Alembic Pharmaceuticals Ltd in the financials table or ratio section above to understand the company's financial performance in terms of earnings generated for shareholders on a per-share basis.

Alembic Pharmaceuticals Balance Sheet Analysis - An Overview

Alembic Pharmaceuticals Equity and Liabilities Growth

Alembic Pharmaceuticals has shown a steady figure in its share capital over the four years from Mar 2020 to Mar 2024, maintaining at Rs Cr. 39.31 from Mar 2021 onwards. A significant growth in total reserves was noted from Mar 2020's Rs Cr. 3,308.32 to a peak of Rs Cr. 5,251.03 in Mar 2022 before a slight decrease to Rs Cr. 4,869.60 by Mar 2024. The company's borrowings saw a drastic reduction to nil from Mar 2022 onwards, showing a strong financial position with decreased leverage.

Alembic Pharmaceuticals Asset growth and Composition

On the assets front, the net block has progressively expanded from Rs Cr. 1,268.11 in Mar 2020 to Rs Cr. 2,535.66 by Mar 2024, indicating ongoing investments in property, plant, and equipment. However, Capital Work In Progress (WIP) saw a significant reduction from its peak in Mar 2022 at Rs Cr. 2,205.80 to Rs Cr. 524.36 by Mar 2024, reflecting a slowdown in new projects or completion of ongoing ones. Current assets have been on an upward trend reaching Rs Cr. 3,029.74 by Mar 2024, suggestive of strong liquidity.

This data is an analysis for the Standalone Balance sheet of Alembic Pharmaceuticals.

Investors looking into the pharma sector might find Alembic Pharmaceuticals an interesting case study amidst the dynamic landscape of the NSE BSE indices.

Read More
X